Get Live Data

IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production
Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to productionView Video
IntelliAM aiming for significant growth with £5 million Aquis IPO
IntelliAM aiming for significant growth with £5 million Aquis IPOView Video

Latest Share Chat

  2. Share Prices
  3. Physiomics Share Price
  4. Physiomics Share News
  5. Physiomics Signs Agreement With Bicycle Therapeutics, Cancer Research

Pin to quick picksPhysiomics Share News (PYC)

Physiomics Information

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.10 (16.667%)
Open: 0.65
High: 0.65
Low: 0.65
Prev. Close: 0.65
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Physiomics Signs Agreement With Bicycle Therapeutics, Cancer Research

Mon, 08th Jul 2019 11:19

(Alliance News) - Medical prediction software developer Physiomics PLC said Monday it has signed an agreement with Nasdaq-listed biopharma firm Bicycle Therapeutics and research charity Cancer Research UK.

The project is expected to be completed during 2019 and will be focused on analysis of clinical data from a phase I/IIa clinical trial of Bicycle Therapeutics's lead program, BT1718, in solid tumours.

The trial is being sponsored by Cancer Research.

On Friday last week, Physiomics won a contract from Bicycle to provide mathematical modelling services for its immune-oncology compounds.

"We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity," said Chief Executive Officer Jim Millen.

Shares in Physiomics were down 3.3% at 2.95 pence on Monday in London.

More News
3 Jul 2024 12:09

TRADING UPDATES: Topps Tiles sales dip; Physiomics completes placing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
3 Jul 2024 10:44

AIM WINNERS & LOSERS: Aptamer rises on AstraZeneca contract

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
14 Jun 2024 19:47

EARNINGS AND TRADING: Sound Energy sells part of Moroccan assets

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
14 Jun 2024 09:51

Physiomics re-engages with DoseMe for personalised dosing software

(Sharecast News) - Physiomics, a mathematical modelling and data science specialist focussed on therapeutics and personalised medicine, has re-engaged with DoseMe to implement its personalised dosing software on the 'DoseMeRx' platform, it announced on Friday.

Read more
13 Jun 2024 10:28

IN BRIEF: Physiomics inks contract with old client worth GBP186,000

Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Wins new contract from "an existing, large client", worth GBP186,000. According to the agreement, the client will use Physiomics' proprietary Virtual Tumour platform to model its targeted oncology agents in combination with other modalities, in order to help inform dose and scheduling decisions. As a result, Physiomics will be entering the next financial year - ending June 30, 2025 - with committed revenue of over GBP500,000.

Read more
13 Jun 2024 09:56

Physiomics wins new contract with existing client

(Sharecast News) - Data sciences business Physiomics said on Thursday that it has been awarded a new contract by an existing, large client.

Read more
7 Jun 2024 12:01

IN BRIEF: Physiomics wins "significant" GBP160,000 contract

Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Says it has been awarded a significant contract by a new UK-based biotech client, which it left unnamed. "This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas," the company says. The project involves the use of Physiomics' Virtual Tumour technology to help guide the phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at GBP161,580 and is anticipated to be completed over the next five months.

Read more
1 Jun 2024 13:01

EXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood Tech

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and Friday this week and not separately reported by Alliance News:

Read more
3 May 2024 14:34

IN BRIEF: Physiomics warns large contracts taken longer than expected

Physiomics PLC - Milton Park, England-based data science company, focused on new therapeutics and personalised medicine solutions - Warns several large contracts have taken longer than expected to be signed. It predicts total income for the year to June 30 will decline to a range of GBP600,000-GBP650,000 as a result. It adds: "The company is in the final stages of negotiation for two projects (one with an existing client and one with a potential new client), the total value of which is expected to be, in aggregate, approximately GBP350,000. Whilst the board anticipates that the contracts for these two projects will be signed in FY24, the majority of the revenue is now expected be recognised in the company's next financial year ending 30 June 2025, and accordingly the board's expectations for FY25 revenues have been correspondingly increased."

Read more
3 May 2024 11:21

Physiomics lowers forecasts amid contract delays

(Sharecast News) - Therapeutics and medicine-focussed mathematical modelling and data science company Physiomics said in an update on Friday that, despite a robust pipeline of potential new business, it had experienced delays in signing several large contracts.

Read more
3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
18 Mar 2024 11:57

IN BRIEF: Physiomics celebrates "substantial" contract with old client

Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a "substantial" new contract by an existing "large pharma" client, though doesn't specify whom the client is. The project, which is valued at GBP178,000, involves involves pharmacokinetic-pharmacodynamic modelling in the field of DNA damage and repair fields. It is designed to help inform clinical dose and scheduling decisions. Physiomics expects this work to be completed over the course of the next six months.

Read more
18 Mar 2024 09:43

Physiomics secures 'substantial new contract' with existing pharma client

(Sharecast News) - Mathematical modelling and data science company Physiomics has been awarded "a substantial new contract" by an existing large pharmaceutical client.

Read more
7 Mar 2024 14:24

Physiomics reports higher interim revenue; loss narrows

(Alliance News) - Physiomics PLC on Thursday reported higher interim revenue and a narrowed loss.

Read more
7 Mar 2024 12:50

Physiomics revenue rises, losses narrow in first half

(Sharecast News) - Physiomics reported revenue of £0.37m in its interim results on Thursday, up from the £0.34m it recorded a year earlier.

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.